A SUCTION BLISTER MODEL TO CHARACTERIZE EPIDERMAL WOUND HEALING AND EVALUATE THE EFFICACY OF THE TOPICAL WOUND HEALING AGENT INM-755 IN HEALTHY VOLUNTEERS.

Wound healing challenge model drug development non-invasive imaging

Journal

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982

Informations de publication

Date de publication:
29 Jul 2024
Historique:
received: 13 05 2024
revised: 15 07 2024
accepted: 27 07 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 31 7 2024
Statut: aheadofprint

Résumé

Non-healing wounds represent a substantial medical burden with few effective treatments available. To address this challenge, we developed a novel epidermal wound healing model using suction blisters in healthy volunteers. This model allowed for the comprehensive assessment of wound healing dynamics and the evaluation of INM-755, a topical cream containing cannabinol, as a potential therapeutic agent. Two clinical studies were conducted: an observational study and an interventional study. In both studies, healthy volunteers underwent a suction blister procedure on their lower back, creating open epidermal wounds. Wound healing parameters were assessed using advanced imaging systems. Skin barrier function and perfusion were evaluated through trans epidermal water loss (TEWL) and dynamic optical coherence tomography (D-OCT), respectively. The observational study demonstrated the successful and reproducible Induction of blisters and the removal of epidermal sheet, enabling quantifiable measurements of wound healing parameters over time. Re-epithelialization was observed, revealing recovery of skin barrier function and perfusion. In the interventional study, differences of treatments over time were quantified using the above-described techniques. Despite differences from disease-specific blistering, our developed model provides a valuable platform for studying wound healing mechanisms and assessing novel therapeutic interventions. The sensitivity to treatment effects demonstrated in our study underscores the potential utility of this model in early-phase clinical drug development programs targeting wound healing disorders.

Identifiants

pubmed: 39084539
pii: S0928-0987(24)00179-9
doi: 10.1016/j.ejps.2024.106867
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106867

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The Authors declare no conflict of interest

Auteurs

Wouter Ten Voorde (WT)

Centre for Human Drug Research, Leiden, the Netherlands; Leiden University Medical Centre, Leiden, the Netherlands.

Selinde Wind (S)

Centre for Human Drug Research, Leiden, the Netherlands; Leiden University Medical Centre, Leiden, the Netherlands.

Ismahaan Abdisalaam (I)

Centre for Human Drug Research, Leiden, the Netherlands; Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands.

Alexandra Mancini (A)

InMed Pharmaceuticals Inc. Vancouver, Canada.

Feeke Linders (F)

Centre for Human Drug Research, Leiden, the Netherlands.

Manon A A Jansen (MAA)

Centre for Human Drug Research, Leiden, the Netherlands.

Tessa Niemeyer-van der Kolk (TN)

Centre for Human Drug Research, Leiden, the Netherlands.

Jacobus Burggraaf (J)

Centre for Human Drug Research, Leiden, the Netherlands; Leiden University Medical Centre, Leiden, the Netherlands.

Robert Rissmann (R)

Centre for Human Drug Research, Leiden, the Netherlands; Leiden University Medical Centre, Leiden, the Netherlands; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. Electronic address: rrissmann@chdr.nl.

Classifications MeSH